Precigen (NASDAQ:PGEN) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Precigen (NASDAQ:PGEN) from a sell rating to a hold rating in a research note published on Saturday morning.

A number of other equities analysts have also issued reports on the company. HC Wainwright raised their price target on Precigen from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Citizens Jmp upped their price target on Precigen from $8.00 to $9.00 and gave the stock a “market outperform” rating in a report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $9.50.

Precigen Trading Down 5.7%

NASDAQ PGEN opened at $3.67 on Friday. The company has a debt-to-equity ratio of 4.46, a current ratio of 3.09 and a quick ratio of 3.95. Precigen has a 12 month low of $1.11 and a 12 month high of $5.47. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -2.74 and a beta of 1.10. The firm’s fifty day moving average price is $4.08 and its 200 day moving average price is $3.97.

Precigen (NASDAQ:PGEN) last posted its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.09. The business had revenue of $4.57 million for the quarter, compared to analysts’ expectations of $8.29 million. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%. On average, sell-side analysts expect that Precigen will post -0.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Xponance LLC increased its stake in Precigen by 21.3% during the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,496 shares during the period. BNP Paribas Financial Markets lifted its holdings in Precigen by 6.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,993 shares in the last quarter. Composition Wealth LLC boosted its position in Precigen by 16.5% in the 4th quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 3,000 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Precigen by 5.2% during the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock worth $263,000 after acquiring an additional 3,137 shares during the last quarter. Finally, Strs Ohio lifted its stake in shares of Precigen by 6.8% in the third quarter. Strs Ohio now owns 50,400 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 3,200 shares in the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen News Summary

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (Q3‑2026 to FY2030) and reiterated a Buy rating with a $10 price target, projecting material earnings improvement through 2030 — supportive for longer‑term upside.
• Positive Sentiment: Citizens/JMP lifted its price target to $9 and moved to “market outperform,” adding another near‑term bullish analyst signal. Benzinga coverage
• Positive Sentiment: Management says PAPZIMEOS launch is accelerating with broad U.S. payer coverage and expects Q1 revenue to exceed $18M; company guidance points toward cash‑flow breakeven in 2026 if momentum continues. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates…
• Positive Sentiment: Analyst write‑ups highlight PAPZIMEOS’s blockbuster potential and model scenarios that imply meaningful upside from current levels, underpinning buy‑side interest. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Q4 earnings materials and call transcripts are available for investors to parse execution details and commercial cadence; management commentary will drive near‑term sentiment. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Q4 beat on EPS (small) but revenue missed estimates — mixed fundamentals that leave room for both upside on commercial execution and downside if sales growth stalls. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: After a roughly 145% one‑year surge, some coverage questions valuation and whether near‑term upside is already priced in — pieces asking “Is it too late?” amplify profit‑taking pressure. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?
• Negative Sentiment: High trading volume and short‑term pullback risk: elevated turnover after the rally can accelerate declines if upcoming sales data or payer dynamics disappoint — the main near‑term risk for the stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.